Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Carbasalate→

Carbasalate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
93803-83-9
Molecular formula
C19H18CaN2O9
Molecular weight
458.4 g/mol
Drug class
Carbasalate calciumaspirin-releasing salicylate complex
Mechanism of action
Dissociates to acetylsalicylic acid (aspirin) and calcium/urea components. Aspirin irreversibly acetylates cyclo-oxygenase-1 and cyclo-oxygenase-2, reducing prostaglandin and thromboxane synthesis and producing analgesic, antipyretic, anti-inflammatory and antiplatelet effects depending on dose.
Indications / reported uses
  • Product-specific indications may include pain and fever relief or antiplatelet use, depending on formulation and country authorisation. Do not infer aspirin low-dose antiplatelet indication for every carbasalate calcium preparation.

Sources: NLM MeSH — Carbasalate calcium · PubMed — Carbasalate calcium pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Carbasalate Environmental Risk Assessment (ERA) (the Carbasalate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.